AbbVie stock slammed after disappointing results for cancer drug acquired in $5.8 billion deal
AbbVie Inc.’s $5.8 billion acquisition of biotech unicorn Stemcentrx back in 2016 was an expensive bet on the company’s lead product, small cell lung cancer drug Rova-T, and its therapy’s targeted approach to certain proteins that are highly expressed in the disease.
